Results from phase III NATALEE trial of Kisqal (ribociclib) + endocrine therapy show sustained reduction of recurrence in HER+/HER2- early breast cancer – Novartis
Novartis announced results from an updated analysis of the pivotal Phase III NATALEE trial of Kisqal (ribociclib) that underscore the extended efficacy beyond the duration of treatment in… read more.
